Schwab US Dividend Equity ETF Sees Positive Fund Flows

Schwab US Dividend Equity ETF ( $SCHD ) has risen by 1.86% in the past week. It has experienced a 5-day net inflow of $22.31 million.
This is due, in part, to market sentiment on some of the ETF’s largest holdings. For example:

• Merck & Company has been in the spotlight recently with a mix of analyst opinions and strategic moves. Bernstein analyst Courtney Breen maintained a Hold rating, while Morgan Stanley also echoed this sentiment. However, Wells Fargo’s Mohit Bansal upgraded Merck to a Buy, citing confidence in the company’s pipeline and future growth prospects, despite the looming patent expiration of its cancer drug Keytruda. Merck’s stock rose about 4% following this upgrade. The company is also making strategic acquisitions, like Cidara Therapeutics, to diversify its portfolio and mitigate future revenue losses.
• Amgen Inc has received positive attention from analysts, with Piper Sandler’s David Amsellem maintaining a Buy rating and setting a price target of $381.00. The stock is close to its 52-week high, reflecting investor optimism. Amgen’s consensus rating is a Moderate Buy, with a slight downside from current levels. The company’s strong position in the healthcare sector and recent analyst coverage suggest a stable outlook.
• Cisco is making strides in the tech industry through its collaboration with IBM on quantum computing. This partnership aims to create a powerful quantum network by the early 2030s, potentially revolutionizing internet capabilities. Cisco’s role in developing the networking technology for quantum computers highlights its strategic focus on innovation and future growth. This move aligns with Cisco’s broader vision of integrating advanced technologies to solve complex problems and enhance global connectivity.